A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30actual
Sites
11
Country
Russia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-24 | actual | When the study began enrolling |
| Primary completion | 2026-05-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer
Interventions
- Drug: Oleclumab
- Drug: Durvalumab
Primary outcome
what the primary-completion date above is the date OFProgression free survival (PFS) at 12 months
measured From date of first dose until 12 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed